BRPI0711159A2

BRPI0711159A2 - compostos terapêuticos

compostos terapêuticos Download PDF

Info

Publication number: BRPI0711159A2
Authority: BR; Brazil
Prior art keywords: phenyl; hydroxyhexyl; cyclopentyl; compound according; compound
Prior art date: 2006-05-03

Application number

BRPI0711159-2A

Other languages

English (en)

Portuguese (pt)

Inventor

Yariv Donde

Jeremiah H Nguyen

Original Assignee

Allergan Inc

Priority date

2006-05-03

Filing date

2007-05-02

Publication date

2011-08-23

2007-05-02 Application filed by Allergan Inc filed Critical Allergan Inc

2011-08-23 Publication of BRPI0711159A2 publication Critical patent/BRPI0711159A2/pt

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 208
230000001225 therapeutic effect Effects 0.000 title description 5
239000000203 mixture Substances 0.000 claims abstract description 28
239000003814 drug Substances 0.000 claims abstract description 25
-1 6-hexyl Chemical group 0.000 claims description 118
150000003839 salts Chemical class 0.000 claims description 40
238000000034 method Methods 0.000 claims description 38
239000000651 prodrug Substances 0.000 claims description 32
229940002612 prodrug Drugs 0.000 claims description 32
125000004432 carbon atom Chemical group C* 0.000 claims description 26
208000010412 Glaucoma Diseases 0.000 claims description 21
229910052717 sulfur Inorganic materials 0.000 claims description 20
229910052760 oxygen Inorganic materials 0.000 claims description 19
239000002253 acid Substances 0.000 claims description 18
150000002148 esters Chemical class 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 16
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 14
125000001072 heteroaryl group Chemical group 0.000 claims description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
229910052799 carbon Inorganic materials 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 11
125000003831 tetrazolyl group Chemical group 0.000 claims description 10
150000001408 amides Chemical class 0.000 claims description 9
125000000524 functional group Chemical group 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 8
239000004305 biphenyl Substances 0.000 claims description 8
235000010290 biphenyl Nutrition 0.000 claims description 7
239000007788 liquid Substances 0.000 claims description 7
150000007524 organic acids Chemical group 0.000 claims description 7
125000003107 substituted aryl group Chemical group 0.000 claims description 7
CJNGVNUIMNHSQW-IAZWUMQMSA-N 5-[3-[(1s,2s)-3,3-dichloro-2-[4-(1-hydroxyhexyl)phenyl]cyclopentyl]propyl]thiophene-2-carboxylic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(Cl)(Cl)CC[C@@H]1CCCC1=CC=C(C(O)=O)S1 CJNGVNUIMNHSQW-IAZWUMQMSA-N 0.000 claims description 6
206010030043 Ocular hypertension Diseases 0.000 claims description 6
FRLRPPZPRINRRM-DWJMJQJNSA-N (z)-7-[(1r,2s,3r)-3-chloro-2-[4-(1-hydroxyhexyl)phenyl]cyclopentyl]hept-5-enoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(O)=O)CC[C@H]1Cl FRLRPPZPRINRRM-DWJMJQJNSA-N 0.000 claims description 5
BTEGTUSVWYVMNV-VTQWZKGGSA-N (z)-7-[(1s,5s)-5-[4-(1-hydroxyhexyl)phenyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)C=C[C@@H]1C\C=C/CCCC(O)=O BTEGTUSVWYVMNV-VTQWZKGGSA-N 0.000 claims description 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
150000004702 methyl esters Chemical class 0.000 claims description 4
HVGTWJSGLFRWPK-SXVPRHBSSA-N propan-2-yl 5-[3-[(1s,2s)-2-[4-(1-hydroxyhexyl)phenyl]-3-oxocyclopentyl]propyl]thiophene-2-carboxylate Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1CCCC1=CC=C(C(=O)OC(C)C)S1 HVGTWJSGLFRWPK-SXVPRHBSSA-N 0.000 claims description 4
IKQQTWXFRKAKLV-XZOYJPPVSA-N 5-[3-[(1s,2s)-2-[4-[(1s)-1-hydroxyhexyl]phenyl]-3-oxocyclopentyl]propyl]thiophene-2-carboxylic acid Chemical compound C1=CC([C@@H](O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1CCCC1=CC=C(C(O)=O)S1 IKQQTWXFRKAKLV-XZOYJPPVSA-N 0.000 claims description 3
QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 3
IKQQTWXFRKAKLV-VNZMSGEBSA-N 5-[3-[(1s,2s)-2-[4-[(1r)-1-hydroxyhexyl]phenyl]-3-oxocyclopentyl]propyl]thiophene-2-carboxylic acid Chemical compound C1=CC([C@H](O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1CCCC1=CC=C(C(O)=O)S1 IKQQTWXFRKAKLV-VNZMSGEBSA-N 0.000 claims description 2
101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
125000002950 monocyclic group Chemical group 0.000 claims description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 abstract 1
235000002639 sodium chloride Nutrition 0.000 description 41
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
239000000243 solution Substances 0.000 description 27
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
125000001424 substituent group Chemical group 0.000 description 22
150000001732 carboxylic acid derivatives Chemical class 0.000 description 20
239000000460 chlorine Substances 0.000 description 19
229940079593 drug Drugs 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
125000003118 aryl group Chemical group 0.000 description 16
125000001183 hydrocarbyl group Chemical group 0.000 description 15
210000004027 cell Anatomy 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 12
238000009739 binding Methods 0.000 description 10
201000010099 disease Diseases 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
125000004429 atom Chemical group 0.000 description 9
230000027455 binding Effects 0.000 description 9
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
101001117519 Homo sapiens Prostaglandin E2 receptor EP2 subtype Proteins 0.000 description 8
208000017442 Retinal disease Diseases 0.000 description 8
206010046851 Uveitis Diseases 0.000 description 8
239000000872 buffer Substances 0.000 description 8
125000004122 cyclic group Chemical group 0.000 description 8
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
229960002986 dinoprostone Drugs 0.000 description 8
229920000642 polymer Polymers 0.000 description 8
150000003180 prostaglandins Chemical class 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 7
230000001154 acute effect Effects 0.000 description 7
210000001072 colon Anatomy 0.000 description 7
230000000670 limiting effect Effects 0.000 description 7
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
101000836978 Homo sapiens Sperm-associated antigen 11B Proteins 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000000556 agonist Substances 0.000 description 6
125000003342 alkenyl group Chemical group 0.000 description 6
125000000304 alkynyl group Chemical group 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
239000011734 sodium Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
206010020772 Hypertension Diseases 0.000 description 5
208000002367 Retinal Perforations Diseases 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
SDIGDHKNZDKUCO-JCMQYMRCSA-N (z)-7-[(1r,2s,3r)-3-hydroxy-2-[4-(1-hydroxyhexyl)phenyl]cyclopentyl]hept-5-enoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(O)=O)CC[C@H]1O SDIGDHKNZDKUCO-JCMQYMRCSA-N 0.000 description 4
206010012689 Diabetic retinopathy Diseases 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 4
102000000471 Prostaglandin F receptors Human genes 0.000 description 4
108050008995 Prostaglandin F receptors Proteins 0.000 description 4
206010038923 Retinopathy Diseases 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
208000002780 macular degeneration Diseases 0.000 description 4
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
229940094443 oxytocics prostaglandins Drugs 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000002207 retinal effect Effects 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
RRXDAWWFRMARNU-VTQWZKGGSA-N (z)-7-[(1r,2s)-2-[4-(1-hydroxyhexyl)phenyl]-3-oxocyclopentyl]hept-5-enoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1C\C=C/CCCC(O)=O RRXDAWWFRMARNU-VTQWZKGGSA-N 0.000 description 3
FRLRPPZPRINRRM-HSDQVZFISA-N (z)-7-[(1r,2s,3s)-3-chloro-2-[4-(1-hydroxyhexyl)phenyl]cyclopentyl]hept-5-enoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(O)=O)CC[C@@H]1Cl FRLRPPZPRINRRM-HSDQVZFISA-N 0.000 description 3
IKQQTWXFRKAKLV-HIHYIXDKSA-N 5-[3-[(1s,2s)-2-[4-(1-hydroxyhexyl)phenyl]-3-oxocyclopentyl]propyl]thiophene-2-carboxylic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1CCCC1=CC=C(C(O)=O)S1 IKQQTWXFRKAKLV-HIHYIXDKSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
206010009900 Colitis ulcerative Diseases 0.000 description 3
208000011231 Crohn disease Diseases 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
101150109738 Ptger4 gene Proteins 0.000 description 3
206010038848 Retinal detachment Diseases 0.000 description 3
206010038910 Retinitis Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
201000006704 Ulcerative Colitis Diseases 0.000 description 3
239000000048 adrenergic agonist Substances 0.000 description 3
210000002159 anterior chamber Anatomy 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000001914 filtration Methods 0.000 description 3
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
208000014674 injury Diseases 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
WJAOXKIMMSZGNH-ALVJRTDLSA-N methyl 5-[3-[(1s,2s)-2-[4-(1-hydroxyhexyl)phenyl]-3-oxocyclopentyl]propyl]thiophene-2-carboxylate Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1CCCC1=CC=C(C(=O)OC)S1 WJAOXKIMMSZGNH-ALVJRTDLSA-N 0.000 description 3
125000001624 naphthyl group Chemical group 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
230000004264 retinal detachment Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
230000008733 trauma Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 2
KSVMFWCSXXDEAC-HIHYIXDKSA-N 5-[3-[(1s,5s)-5-[4-(1-hydroxyhexyl)phenyl]-4-oxocyclopent-2-en-1-yl]propyl]thiophene-2-carboxylic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)C=C[C@@H]1CCCC1=CC=C(C(O)=O)S1 KSVMFWCSXXDEAC-HIHYIXDKSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
208000009137 Behcet syndrome Diseases 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
208000014882 Carotid artery disease Diseases 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
206010012688 Diabetic retinal oedema Diseases 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
101001073427 Homo sapiens Prostaglandin E2 receptor EP1 subtype Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 2
102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 2
102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 2
201000007527 Retinal artery occlusion Diseases 0.000 description 2
201000007737 Retinal degeneration Diseases 0.000 description 2
208000007014 Retinitis pigmentosa Diseases 0.000 description 2
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
208000027073 Stargardt disease Diseases 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
201000005485 Toxoplasmosis Diseases 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
206010064930 age-related macular degeneration Diseases 0.000 description 2
230000032683 aging Effects 0.000 description 2
125000002723 alicyclic group Chemical group 0.000 description 2
229960000711 alprostadil Drugs 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
125000000751 azo group Chemical group [*]N=N[*] 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000000227 bioadhesive Substances 0.000 description 2
239000012267 brine Substances 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
150000001733 carboxylic acid esters Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000005660 chlorination reaction Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000000064 cholinergic agonist Substances 0.000 description 2
229960004409 cloprostenol Drugs 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
201000011190 diabetic macular edema Diseases 0.000 description 2
150000002066 eicosanoids Chemical class 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229930182480 glucuronide Natural products 0.000 description 2
150000008134 glucuronides Chemical class 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
238000003328 mesylation reaction Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
150000004866 oxadiazoles Chemical class 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
239000006179 pH buffering agent Substances 0.000 description 2
230000036407 pain Effects 0.000 description 2
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229960001416 pilocarpine Drugs 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
208000004644 retinal vein occlusion Diseases 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229960004249 sodium acetate Drugs 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
208000006379 syphilis Diseases 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
150000003568 thioethers Chemical group 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
238000009736 wetting Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
FJLRGFADCXTJNV-IIBYNOLFSA-N (1S,2R)-1-(2,3-dihydro-1-benzothiophen-5-yl)-2-(4-phenylbutylamino)propan-1-ol Chemical compound N([C@H](C)[C@@H](O)C=1C=C2CCSC2=CC=1)CCCCC1=CC=CC=C1 FJLRGFADCXTJNV-IIBYNOLFSA-N 0.000 description 1
ZNMXKJDERFMXNF-ZETCQYMHSA-N (1r)-1-(2-hydroxy-1,3,2-benzodioxaborol-5-yl)-2-(methylamino)ethanol Chemical compound CNC[C@H](O)C1=CC=C2OB(O)OC2=C1 ZNMXKJDERFMXNF-ZETCQYMHSA-N 0.000 description 1
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
GYYDPBCUIJTIBM-DYOGSRDZSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-[[(4r,5s)-4-hydroxy-3-methyl-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-methoxyoxane-3,5-diol Chemical compound O[C@@H]1[C@@H](OC)[C@@H](O)[C@@H](CO)OC1OC1[C@H]2OCC1OC(C)[C@H]2O GYYDPBCUIJTIBM-DYOGSRDZSA-N 0.000 description 1
ZIDQIOZJEJFMOH-JKSUJKDBSA-N (3R,4S)-BW 245C Chemical compound C([C@@H](O)C1CCCCC1)CN1[C@@H](CCCCCCC(O)=O)C(=O)NC1=O ZIDQIOZJEJFMOH-JKSUJKDBSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
MSBDRASPHIQVEM-UODATKDOSA-N (z)-7-[(1r,2s)-2-[4-(1,2-dihydroxyhexyl)phenyl]-3-oxocyclopentyl]hept-5-enoic acid Chemical compound C1=CC(C(O)C(O)CCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1C\C=C/CCCC(O)=O MSBDRASPHIQVEM-UODATKDOSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 1
FSGCSTPOPBJYSX-VEIFNGETSA-N 131543-23-2 Chemical compound CS(O)(=O)=O.C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 FSGCSTPOPBJYSX-VEIFNGETSA-N 0.000 description 1
ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
FPWIKXUUXCOYRJ-XTBBCBASSA-N 4-[2-[(1s,2s)-2-[4-(1-hydroxyhexyl)phenyl]-3-oxocyclopentyl]ethyl]benzoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1CCC1=CC=C(C(O)=O)C=C1 FPWIKXUUXCOYRJ-XTBBCBASSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000004300 Atrophic Gastritis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229940121840 Beta adrenoreceptor antagonist Drugs 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
229940123406 CCK B receptor antagonist Drugs 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
206010007027 Calculus urinary Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000009447 Cardiac Edema Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000033379 Chorioretinopathy Diseases 0.000 description 1
208000005590 Choroidal Neovascularization Diseases 0.000 description 1
206010060823 Choroidal neovascularisation Diseases 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010018325 Congenital glaucomas Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010058202 Cystoid macular oedema Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
102100025269 DENN domain-containing protein 2B Human genes 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012565 Developmental glaucoma Diseases 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
208000019878 Eales disease Diseases 0.000 description 1
DWAWDSVKAUWFHC-UHFFFAOYSA-N Emopamil Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(C)CCC1=CC=CC=C1 DWAWDSVKAUWFHC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000001351 Epiretinal Membrane Diseases 0.000 description 1
241001125671 Eretmochelys imbricata Species 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
208000031969 Eye Hemorrhage Diseases 0.000 description 1
208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
102000004300 GABA-A Receptors Human genes 0.000 description 1
108090000839 GABA-A Receptors Proteins 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000036495 Gastritis atrophic Diseases 0.000 description 1
229940122459 Glutamate antagonist Drugs 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000722264 Homo sapiens DENN domain-containing protein 2B Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
206010051232 Hyperphosphaturia Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010058558 Hypoperfusion Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010022557 Intermediate uveitis Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
208000001344 Macular Edema Diseases 0.000 description 1
206010025412 Macular dystrophy congenital Diseases 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
208000035719 Maculopathy Diseases 0.000 description 1
208000029725 Metabolic bone disease Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
208000009857 Microaneurysm Diseases 0.000 description 1
206010028034 Mouth ulceration Diseases 0.000 description 1
208000010164 Multifocal Choroiditis Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010068960 Narrow anterior chamber angle Diseases 0.000 description 1
206010064997 Necrotising retinitis Diseases 0.000 description 1
206010065673 Nephritic syndrome Diseases 0.000 description 1
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
206010065700 Ocular sarcoidosis Diseases 0.000 description 1
206010030302 Oliguria Diseases 0.000 description 1
206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
208000007117 Oral Ulcer Diseases 0.000 description 1
208000003076 Osteolysis Diseases 0.000 description 1
206010049088 Osteopenia Diseases 0.000 description 1
208000027067 Paget disease of bone Diseases 0.000 description 1
206010065373 Papillophlebitis Diseases 0.000 description 1
208000004788 Pars Planitis Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000027954 Poultry disease Diseases 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
102000008866 Prostaglandin E receptors Human genes 0.000 description 1
108010088540 Prostaglandin E receptors Proteins 0.000 description 1
102000015433 Prostaglandin Receptors Human genes 0.000 description 1
108010050183 Prostaglandin Receptors Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
206010064714 Radiation retinopathy Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000008709 Retinal Telangiectasis Diseases 0.000 description 1
208000032430 Retinal dystrophy Diseases 0.000 description 1
206010038897 Retinal tear Diseases 0.000 description 1
206010038915 Retinitis viral Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 description 1
101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
208000014286 Serpiginous choroiditis Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
206010040925 Skin striae Diseases 0.000 description 1
239000004133 Sodium thiosulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
208000011622 Testicular disease Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010044269 Toxocariasis Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000009911 Urinary Calculi Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000029977 White Dot Syndromes Diseases 0.000 description 1
201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 description 1
208000017441 X-linked retinoschisis Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
201000001326 acute closed-angle glaucoma Diseases 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000003973 alkyl amines Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960002610 apraclonidine Drugs 0.000 description 1
IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
150000007860 aryl ester derivatives Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
229960002992 barnidipine Drugs 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229960004324 betaxolol Drugs 0.000 description 1
CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
229960002470 bimatoprost Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
208000016738 bone Paget disease Diseases 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
229960003679 brimonidine Drugs 0.000 description 1
229960000722 brinzolamide Drugs 0.000 description 1
HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229930003827 cannabinoid Natural products 0.000 description 1
239000003557 cannabinoid Substances 0.000 description 1
229940065144 cannabinoids Drugs 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
229910002090 carbon oxide Inorganic materials 0.000 description 1
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000006243 carbonyl protecting group Chemical group 0.000 description 1
150000003857 carboxamides Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
201000005849 central retinal artery occlusion Diseases 0.000 description 1
201000005667 central retinal vein occlusion Diseases 0.000 description 1
150000001805 chlorine compounds Chemical group 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
208000027129 choroid disease Diseases 0.000 description 1
208000016644 chronic atrophic gastritis Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940126086 compound 21 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
201000008615 cone dystrophy Diseases 0.000 description 1
208000006623 congenital stationary night blindness Diseases 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
201000010206 cystoid macular edema Diseases 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
229960005081 diclofenamide Drugs 0.000 description 1
GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
229960003933 dorzolamide Drugs 0.000 description 1
IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229960002017 echothiophate Drugs 0.000 description 1
BJOLKYGKSZKIGU-UHFFFAOYSA-N ecothiopate Chemical compound CCOP(=O)(OCC)SCC[N+](C)(C)C BJOLKYGKSZKIGU-UHFFFAOYSA-N 0.000 description 1
229950005455 eliprodil Drugs 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
229950009967 emopamil Drugs 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
229960003072 epinephrine hydrochloride Drugs 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000027950 fever generation Effects 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
229960002011 fludrocortisone Drugs 0.000 description 1
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
229960000326 flunarizine Drugs 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 description 1
229950009951 fluprostenol Drugs 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000007160 gastrointestinal dysfunction Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
244000005709 gut microbiome Species 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000005549 heteroarylene group Chemical group 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
102000052775 human PTGER2 Human genes 0.000 description 1
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
150000007857 hydrazones Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
229960003998 ifenprodil Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960000831 levobunolol Drugs 0.000 description 1
IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
229960001941 lidoflazine Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000005976 liver dysfunction Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
208000029233 macular holes Diseases 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 1
229960004083 methazolamide Drugs 0.000 description 1
FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
ASOAFZZCBIIQQZ-MBRMJFKSSA-N methyl (z)-7-[(1r,2s)-2-(4-hex-1-enylphenyl)-3-oxocyclopentyl]hept-5-enoate Chemical compound C1=CC(C=CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1C\C=C/CCCC(=O)OC ASOAFZZCBIIQQZ-MBRMJFKSSA-N 0.000 description 1
KHIYCHNEBOSPMB-NCUPQMHLSA-N methyl (z)-7-[(1r,2s)-2-[4-(1,2-dihydroxyhexyl)phenyl]-3-oxocyclopentyl]hept-5-enoate Chemical compound C1=CC(C(O)C(O)CCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1C\C=C/CCCC(=O)OC KHIYCHNEBOSPMB-NCUPQMHLSA-N 0.000 description 1
AWOIJORKNPVXHK-RCPXMSJASA-N methyl (z)-7-[(1r,2s)-2-[4-(1-acetyloxyhexyl)phenyl]-3-oxocyclopentyl]hept-5-enoate Chemical compound C1=CC(C(OC(C)=O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1C\C=C/CCCC(=O)OC AWOIJORKNPVXHK-RCPXMSJASA-N 0.000 description 1
XZBWXMIQUKTVGA-QLDGFJOXSA-N methyl (z)-7-[(1r,2s,3r)-2-[4-(1-acetyloxyhexyl)phenyl]-3-chlorocyclopentyl]hept-5-enoate Chemical compound C1=CC(C(OC(C)=O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(=O)OC)CC[C@H]1Cl XZBWXMIQUKTVGA-QLDGFJOXSA-N 0.000 description 1
GLGSNOOIKQPWOW-QLDGFJOXSA-N methyl (z)-7-[(1r,2s,3r)-2-[4-(1-acetyloxyhexyl)phenyl]-3-hydroxycyclopentyl]hept-5-enoate Chemical compound C1=CC(C(OC(C)=O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(=O)OC)CC[C@H]1O GLGSNOOIKQPWOW-QLDGFJOXSA-N 0.000 description 1
XZBWXMIQUKTVGA-VYBVDFQCSA-N methyl (z)-7-[(1r,2s,3s)-2-[4-(1-acetyloxyhexyl)phenyl]-3-chlorocyclopentyl]hept-5-enoate Chemical compound C1=CC(C(OC(C)=O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(=O)OC)CC[C@@H]1Cl XZBWXMIQUKTVGA-VYBVDFQCSA-N 0.000 description 1
GLGSNOOIKQPWOW-VYBVDFQCSA-N methyl (z)-7-[(1r,2s,3s)-2-[4-(1-acetyloxyhexyl)phenyl]-3-hydroxycyclopentyl]hept-5-enoate Chemical compound C1=CC(C(OC(C)=O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(=O)OC)CC[C@@H]1O GLGSNOOIKQPWOW-VYBVDFQCSA-N 0.000 description 1
BFYVCMUQQGHVJO-RCPXMSJASA-N methyl (z)-7-[(1s,5s)-5-[4-(1-acetyloxyhexyl)phenyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoate Chemical compound C1=CC(C(OC(C)=O)CCCCC)=CC=C1[C@H]1C(=O)C=C[C@@H]1C\C=C/CCCC(=O)OC BFYVCMUQQGHVJO-RCPXMSJASA-N 0.000 description 1
HKYBFRFDZZEOAG-UIEAFCHPSA-N methyl 5-[3-[(1s,2s)-3,3-dichloro-2-[4-(1-hydroxyhexyl)phenyl]cyclopentyl]propyl]thiophene-2-carboxylate Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(Cl)(Cl)CC[C@@H]1CCCC1=CC=C(C(=O)OC)S1 HKYBFRFDZZEOAG-UIEAFCHPSA-N 0.000 description 1
244000005706 microflora Species 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
201000002165 neuroretinitis Diseases 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
UQDVHJGNIFVBLG-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O UQDVHJGNIFVBLG-UHFFFAOYSA-N 0.000 description 1
208000008940 ocular tuberculosis Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
208000008798 osteoma Diseases 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
229940096826 phenylmercuric acetate Drugs 0.000 description 1
PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000000649 photocoagulation Effects 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
150000004291 polyenes Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
201000004849 posterior scleritis Diseases 0.000 description 1
201000002267 posterior uveal melanoma Diseases 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
201000000484 premenstrual tension Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
CMOSCANUCNWGSZ-QRJMOIHYSA-N propan-2-yl (z)-7-[(1r,2s)-2-[4-(1-hydroxyhexyl)phenyl]-3-oxocyclopentyl]hept-5-enoate Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)CC[C@@H]1C\C=C/CCCC(=O)OC(C)C CMOSCANUCNWGSZ-QRJMOIHYSA-N 0.000 description 1
NQHZAAIFVSRDLS-KAMMIXIRSA-N propan-2-yl (z)-7-[(1r,2s,3r)-3-hydroxy-2-[4-(1-hydroxyhexyl)phenyl]cyclopentyl]hept-5-enoate Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@@H]1[C@@H](C\C=C/CCCC(=O)OC(C)C)CC[C@H]1O NQHZAAIFVSRDLS-KAMMIXIRSA-N 0.000 description 1
OGSFDILDOFBTNJ-QRJMOIHYSA-N propan-2-yl (z)-7-[(1s,5s)-5-[4-(1-hydroxyhexyl)phenyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoate Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@H]1C(=O)C=C[C@@H]1C\C=C/CCCC(=O)OC(C)C OGSFDILDOFBTNJ-QRJMOIHYSA-N 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
230000010344 pupil dilation Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004258 retinal degeneration Effects 0.000 description 1
239000000790 retinal pigment Substances 0.000 description 1
201000007714 retinoschisis Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
229960000888 rimantadine Drugs 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229960000581 salicylamide Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
230000035939 shock Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940037001 sodium edetate Drugs 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
208000009056 telangiectasis Diseases 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
229950004945 tibalosin Drugs 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
229960005221 timolol maleate Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000001585 trabecular meshwork Anatomy 0.000 description 1
229960002368 travoprost Drugs 0.000 description 1
MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
229950008081 unoprostone isopropyl Drugs 0.000 description 1
208000008281 urolithiasis Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1